Press Releases Search View

Select Category

Recent News

Search By:

Search By Release Date

85 Record(s) Found. Displaying Page 1:

1 2 3 4 5 [Next >>]

Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
Print \| More options ▼ View RSS Feed
Release Date: 18-Aug-08 Author or Contact:
ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI ...
Click to read Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America

Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen
Print \| More options ▼ View RSS Feed
Release Date: 18-Aug-08 Author or Contact: Joseph Podolski
Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that based on the robust efficacy demonstrated by Proellex® in the interim assessment of the Company�s Phase II endometriosis study, there are sufficient patients currently enrolled to provide for adequate power calculations for the Phase III endometriosis trials. Because of the profound effect noted in this interim analysis, the Company has decided to curtail further patient ...
Click to read Repros Therapeutics Inc. Provides Update for US Phase II Endometriosis Study and Completion of QT Interval Dose Selection Screen

Introgen's ADVEXIN(R) MAA Accepted for Review by European Medicines Agency
Print \| More options ▼ View RSS Feed
Release Date: 18-Aug-08 Author or Contact: Channing Burke
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, and its subsidiary Gendux Molecular Limited, today announced that the European Medicines Agency (EMEA) has accepted for review the company's Marketing Authrorization Application (MAA) for ADVEXIN(R) (p53 tumor suppressor therapy) for the treatment of recurrent, refractory squamous cell carcinoma of the head and neck. ADVEXIN is an innovative gene ...
Click to read Introgen's ADVEXIN(R) MAA Accepted for Review by European Medicines Agency

Power3 Medical Products, Inc. Provides Progress Report - NuroPro(R) Clinical Validation Study of Serum Biomarkers for Alzheimer's Disease
Print \| More options ▼ View RSS Feed
Release Date: 13-Aug-08 Author or Contact: Steven B. Rash
Power3 Medical Products, Inc. (OTCBB:PWRM - News), a leading proteomics company specializing in the development and commercialization of diagnostic tests for early detection of breast cancer and neurodegenerative diseases, is providing an interim status report of its international validation study of the company�s NuroPro® blood serum biomarker test for Alzheimer�s disease. Power3 is currently conducting a 300-patient clinical validation ...
Click to read Power3 Medical Products, Inc. Provides Progress Report - NuroPro(R) Clinical Validation Study of Serum Biomarkers for Alzheimer's Disease

Opexa Therapeutics Completes $3 Million Financing
Print \| More options ▼ View RSS Feed
Release Date: 13-Aug-08 Author or Contact:
Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing novel cell therapies for multiple sclerosis, today announced the completion of a private placement financing with total gross proceeds of approximately $3.0 million. Opexa will use the proceeds from the financing to support the ongoing clinical development of Tovaxin, the company�s novel treatment for multiple sclerosis. Top-line data from the company�s Tovaxin Phase IIb clinical trial ...
Click to read Opexa Therapeutics Completes $3 Million Financing

Lexicon Pharmaceuticals Identifies New Drug Candidate for Glaucoma
Print \| More options ▼ View RSS Feed
Release Date: 13-Aug-08 Author or Contact:
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated formal preclinical development of LX7101, a new drug candidate for glaucoma. LX7101 is a small molecule compound that may have application in treating glaucoma by lowering fluid pressure in the eye through a new mechanism of action. Glaucoma is a disease ...
Click to read Lexicon Pharmaceuticals Identifies New Drug Candidate for Glaucoma

Repair Stem Cell Institute Announces Industry's First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
Print \| More options ▼ View RSS Feed
Release Date: 12-Aug-08 Author or Contact: Jack Wynn
To protect potential patients from being unwitting victims in the proliferation of less than competent therapeutics, the Repair Stem Cell Institute LLC (RSCI) (http://www.RepairStemCells.org) and its Scientific Advisory Board (SAB) today announced the establishment of the industry's first standards of excellence for Repair Stem Cells(TM) (RSC) treatment centers worldwide who are using RSC, also known as Adult Stem Cells. Among the ...
Click to read Repair Stem Cell Institute Announces Industry's First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics

OncoVista Announces Initiation of Research Coverage by Status Equity Research
Print \| More options ▼ View RSS Feed
Release Date: 12-Aug-08 Author or Contact:
OncoVista Innovative Therapies Inc. (OTC BB: OVIT.OB), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that Status Equity Research has initiated research coverage on the Company with a rating of Accumulate and a 36 month price target of $16 per share. The research report can be accessed at www.statusequity.com on the �Status Research� tab. ...
Click to read OncoVista Announces Initiation of Research Coverage by Status Equity Research

Introgen Appoints James E. Rothman, Ph.D., to Board of Directors
Print \| More options ▼ View RSS Feed
Release Date: 12-Aug-08 Author or Contact: Channing Burke
Introgen Therapeutics, Inc. (NASDAQ:INGN), a developer of targeted molecular therapies for cancer, today announced the appointment of James E. Rothman, Ph.D., to the Company's board of directors. In September 2008, Dr. Rothman will relocate his laboratory from Columbia University to Yale University where he will serve as the Wallace professor of biomedical sciences, chairman of the Department of Cell Biology and founder of the Yale University ...
Click to read Introgen Appoints James E. Rothman, Ph.D., to Board of Directors

Caris Diagnostics Launches Target GI� for Colon Cancer Patients Coupling Leading Edge Molecular Diagnostics and Anatomic Pathology
Print \| More options ▼ View RSS Feed
Release Date: 11-Aug-08 Author or Contact: Leslie Brille
Caris Diagnostics (Caris Dx), a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing, announced today the offering of Target GI to physicians nationwide. Target GI is designed to provide information on the expression of key molecular targets present in colon cancer, providing physicians the most up-to-date information to help in the ...
Click to read Caris Diagnostics Launches Target GI� for Colon Cancer Patients Coupling Leading Edge Molecular Diagnostics and Anatomic Pathology

Lexicon Pharmaceuticals' Drug Candidate for Irritable Bowel Syndrome Completes Phase 1 Clinical Trial Showing Positive Results
Print \| More options ▼ View RSS Feed
Release Date: 29-Jul-08 Author or Contact: Bobbie Faulkner
July 29, 2008 -- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has successfully completed a Phase 1 multiple-dose escalation study in normal volunteers with LX1031, its oral drug candidate for irritable bowel syndrome (IBS). The company plans to progress the new drug candidate into Phase 2 studies in the fourth quarter. LX1031 ...
Click to read Lexicon Pharmaceuticals' Drug Candidate for Irritable Bowel Syndrome Completes Phase 1 Clinical Trial Showing Positive Results

XOFT INC DISCOVERS ELECTRONIC BRACHYTHERAPY ACCURATELY DELIVERS NON-RADIOACTIVE THERAPY DIRECTLY TO BREAST AND ENDOCAVITARY CANCER SITES
Print \| More options ▼ View RSS Feed
Release Date: 28-Jul-08 Author or Contact: Chris Joseph
The ability of Electronic Brachytherapy to accurately and consistently deliver localized, non-radioactive radiation treatment directly to cancer sites is the focus of a symposium and multiple research papers accepted for presentation at the 50th American Association of Physicists in Medicine Meeting, July 27 � 31 in Houston. According to Xoft, Inc., developer of the Axxent® Electronic Brachytherapy System, positive clinical results from ...
Click to read XOFT INC DISCOVERS ELECTRONIC BRACHYTHERAPY ACCURATELY DELIVERS NON-RADIOACTIVE THERAPY DIRECTLY TO BREAST AND ENDOCAVITARY CANCER SITES

Introgen Announces ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population
Print \| More options ▼ View RSS Feed
Release Date: 23-Jul-08 Author or Contact: Channing Burke
July 23, 2008 -- Introgen Therapeutics, Inc., a developer of targeted molecular therapies for cancer, today reported additional efficacy data from the company's recent regulatory filings seeking approval of ADVEXIN(R) (p53 tumor suppressor therapy) in the United States and Europe. These findings resulted from supportive statistical analyses based on data from the pivotal Phase 3 clinical trial of ADVEXIN in patients with recurrent, refractory ...
Click to read Introgen Announces ADVEXIN(R) Shows Statistically Significant Six-Month and Overall Survival Benefit as Compared to Methotrexate in Prospectively Defined Biomarker Patient Population

Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin� for Multiple Sclerosis
Print \| More options ▼ View RSS Feed
Release Date: 22-Jul-08 Author or Contact: Lynne Hohlfeld
July 22, 2008 -- Opexa Therapeutics, Inc., a company leading in the development of cell therapies for multiple sclerosis (MS) and diabetes, has completed an internal assessment of data from its Phase I/II two year extension study with Tovaxin in patients with MS. While confirming the favorable safety and efficacy profile of Tovaxin, further analysis also confirms both the benefit of consecutive annual treatments with Tovaxin and the advantage of ...
Click to read Opexa Conducts Additional Analysis on Phase I/II Extension Study with Tovaxin� for Multiple Sclerosis

OncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients with Refractory TdT-Positive Leukemia
Print \| More options ▼ View RSS Feed
Release Date: 22-Jul-08 Author or Contact: Alexander Weis
July 22, 2008 -- OncoVista Innovative Therapies, Inc., a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that patient recruitment has commenced in the company's Phase I/II study of cordycepin for the treatment of patients with terminal deoxynucleotidyl transferase (TdT)-positive refractory leukemia. Participating clinical sites include the Dana Farber Cancer ...
Click to read OncoVista Innovative Therapies to Begin Enrolling Patients in a Phase I/II Study of Cordycepin in Patients with Refractory TdT-Positive Leukemia

Repros Therapeutics Inc. Announces That Proellex� Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium
Print \| More options ▼ View RSS Feed
Release Date: 16-Jul-08 Author or Contact: Joseph Podolski
July 16, 2008 -- Repros Therapeutics Inc. today released strong results from its completed extension safety study of Proellex in the chronic treatment of the symptoms associated with uterine fibroids. To date there have been no abnormal histological findings from the endometrial biopsies taken post menses after cessation of drug administration. As of this release, results from 13 women who had endometrial biopsies post menses following last ...
Click to read Repros Therapeutics Inc. Announces That Proellex� Administered to Patients as Cyclic Therapy to Treat the Symptoms of Uterine Fibroids for Up to 30 Months Shows No Adverse Effects on the Endometrium

Opexa�s Phase IIb Study of Tovaxin� Receives Positive Review
Print \| More options ▼ View RSS Feed
Release Date: 8-Jul-08 Author or Contact: Lynne Hohlfeld
July 8, 2008 -- Opexa Therapeutics, Inc., a company leading in the development of cell therapies for multiple sclerosis announced today that the Data Safety Monitoring Board (DSMB) overseeing the on-going Phase IIb clinical study of Tovaxin has recommended that the trial continue unmodified. This positive recommendation follows a regularly scheduled meeting of the DSMB in June and is based upon an evaluation of clinical, magnetic resonance ...
Click to read Opexa�s Phase IIb Study of Tovaxin� Receives Positive Review

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe
Print \| More options ▼ View RSS Feed
Release Date: 3-Jul-08 Author or Contact: C. Channing Burke
July 03, 2008 -- Introgen Therapeutics, Inc. today announced a re-allocation of employees to focus on regulatory review and commercial activities. After years of product development, Introgen is directing corporate spending toward regulatory review programs, commercialization and the future marketing of ADVEXIN therapy. Recently the Company achieved the major corporate milestone of filing for regulatory approval of ADVEXIN cancer therapy in the ...
Click to read Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe

Fifteen Students Launch Into Space Research Internship
Print \| More options ▼ View RSS Feed
Release Date: 1-Jul-08 Author or Contact: Kathy Major
July 1, 2008 -- Fifteen students are spending the summer at NASA Johnson Space Center, working alongside space life scientists and space medicine researchers as part of the National Space Biomedical Research Institute�s Summer Internship Program. As the International Space Station nears completion, these young scientists are getting a taste of health and medical research related to living in space for long periods and to sending humans back ...
Click to read Fifteen Students Launch Into Space Research Internship

Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Print \| More options ▼ View RSS Feed
Release Date: 30-Jun-08 Author or Contact: Channing Burke
June 30, 2008--Introgen Therapeutics, Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting marketing approval for ADVEXIN(R) p53 therapy to treat recurrent, refractory head and neck cancer. Simultaneously, Gendux Molecular Limited, an Introgen subsidiary, submitted a Marketing Authorization Application (MAA) to the European Medicines Evaluation Agency (EMEA) for the same indication. ...
Click to read Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe

1 2 3 4 5 [Next >>]

Contact Us | Site Map |

| OPML | Search This Site | Home
Schipul Web Design | Tendenci� Content Management Software | Privacy | Terms and Conditions